AstraZeneca shares dipped 2% on Friday following a U.S. FDA advisory panel’s 6-3 vote against approving its experimental breast cancer drug, camizestrant. The panel raised concerns over the trial design and the efficacy of early treatment switching, despite acknowledging the drug’s potential. The Phase 3 SERENA-6 trial results indicated a 56% reduction in disease progression risk, but the panel concluded that it did not sufficiently demonstrate improved long-term survival compared to existing therapies.
This setback could impact AstraZeneca’s short-term regulatory prospects, but analysts suggest it won’t significantly derail the company’s broader growth trajectory. Barclays noted that while the panel’s decision is a negative indicator, it did not dismiss the drug’s efficacy outright. Jefferies analysts echoed this sentiment, emphasizing that SERENA-6 represents only a small fraction of AstraZeneca’s ambitious $80 billion sales target for 2030.
Investors should monitor AstraZeneca’s ongoing engagement with the FDA and upcoming data readouts, as the company has a strong pipeline and remains on track to meet its mid-term goals.
Source: cnbc.com